Dutch Green Chemtech Startup Affix Labs Raises €1 Million for European Expansion of Sustainable Insect Repellent
- Tom Sam
- Apr 23
- 2 min read
The funding round, led by VP Capital and Oost NL, accelerates the rollout of flagship product Repeltec and the company’s patented water-based solubility technology at a time when EU pesticide rules are tightening.
NIJMEGEN, Netherlands — April 21, 2026 Affix Labs Group B.V., a Dutch Green Chemtech startup, has closed a €1 million funding round led by VP Capital and Oost NL. The company's surface insect repellent replaces the neurotoxic active ingredients responsible for growing insect resistance with a water-based, controlled-release alternative. The new capital will fund the European rollout.
The Breakthrough: Patented Solubility and Controlled Release
The core innovation is a formulation method that dissolves oily, water-insoluble active ingredients into water-based systems. A controlled-release layer extends efficacy to 12 weeks. The flagship product, Repeltec, is dermatologically tested and contains no neurotoxic compounds.
“Affix Labs fits our investment thesis exactly: scientifically proven technology that replaces harmful chemistry with a durable, effective alternative. We’re proud to back the team as they move into commercial scale-up.” — Erica van Eeghen, Senior Manager Ventures, VP Capital
A Tightening European Regulatory Environment
EU rules on chemical pesticides are tightening. Germany's 2025 self-service ban pulled a broad category of neurotoxic insecticides from open retail shelves, and similar measures are now being adopted in other member states. Repeltec already holds active substance authorisations in Germany, France, Austria, and Norway.
“We invest where innovation creates measurable economic and environmental impact. Affix Labs has a market-ready solution for a global regulatory shift, and we’re pleased to support the next phase of their growth.” — Matthijs Berkelaar, Senior Investment Manager Tech, Oost NL
Commercial Expansion and B2B Partnerships
With the new capital, Affix Labs is expanding distribution in Germany, Austria, France, and Norway, with the UK and Poland to follow. Alongside its consumer product lines, the company is launching a white-label B2B model under the name "Powered by Affix Labs". FMCG companies, hospitality operators, and pest control manufacturers can use it to integrate the technology into their own product ranges.
“We have regulatory authorisations in four markets, a retail-ready product, and a regulatory environment moving in our direction. With this round we can stop proving the concept and start building distribution.” — Stijn de Roover, CEO, Affix Labs
About Affix Labs Affix Labs is a Dutch Green Chemtech startup working to reduce global pesticide dependency. Its patented solubility technology and controlled-release systems create long-lasting, neurotoxic-free barriers that protect people from insects for months at a time.
About Oost NL Oost NL, the East Netherlands Development Agency, strengthens the regional economy on behalf of the Ministry of Economic Affairs and Climate Policy and the provinces of Gelderland and Overijssel. It invests public funds in innovative companies that drive sustainability and economic resilience.
About VP Capital VP Capital is a single family office based in Belgium and the Netherlands, with a 150-year operating history. The firm pursues an impact-first strategy focused on regenerative, net-zero and toxicity-free solutions across energy transition, agrifood, clean technology, and the built environment. VP Capital is B Corp-certified. VP Capital: Driven by Impact.
Media Contact
Tom Sam
Comments